Physician profile
Megan Everett Cody
NPI 1447880034
$4,877.89
in general payments reported to CMS, 2019-2025
26 companies · $2,837 in 2025
The $2,837 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.83 · 2022: $48.76 · 2023: $106 · 2024: $1,796 · 2025: $2,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,478 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,477.68 |
| Education | $261.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $874.55 | 2024-2025 | |
| Janssen Biotech, INC. | $584.09 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $429.23 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $354.87 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $268.28 | 2024-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $257.74 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $256.80 | 2024-2025 | Sotyktu |
| Incyte Corporation | $219.07 | 2023-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $218.67 | 2024-2025 | Aklief, Nemluvio |
| Ucb, INC. | $192.67 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $155.43 | 2024-2025 | |
| Inari Medical, INC. | $153.30 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $143.24 | 2025 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.32 | 2024 | Cabtreo, Jublia, Arazlo |
| Dermavant Sciences, INC. | $105.76 | 2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $90.25 | 2025 | |
| Arcutis Biotherapeutics, INC. | $88.04 | 2024-2025 | Zoryve |
| Relievant Medsystems, INC. | $64.04 | 2021-2022 | |
| Pfizer INC. | $58.16 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.68 | 2023-2024 | Spevigo |
| Botanix Sb INC | $44.04 | 2025 | Sofdra |
| Shockwave Medical, INC | $41.54 | 2021 | |
| Cipher Pharmaceuticals US LLC | $34.78 | 2025 | Spinosad, Natroba |
| Sun Pharmaceutical Industries INC. | $22.33 | 2025 | |
| Baxter Healthcare | $18.01 | 2022 | |
| Penumbra, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Cody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.